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Previewsauthors found that viral expression of
FNDC5 in liver increased Bdnf gene
expression in the hippocampus, whereas
direct application of irisin to cultured
hippocampal neurons did not. This obser-
vation suggests that a FNDC5 cleavage
product other than irisin may mediate
the beneficial effects of exercise on brain.
This exercise factor (EF) remains to be
identified. Based on the findings of the
current study, the EF could be produced
locally in hippocampal neurons or reach
the hippocampus frommuscle via circula-
tion. It would be important to determine
the relative contribution of local versus
systemic EF to exercise-induced Bdnf
gene expression by selective deletion of
the Fndc5 gene in either muscle or hippo-
campus. Since the circulating EF is likely
distributed to every body part, it remains
puzzling why exercise predominantly
increases hippocampal Bdnf gene ex-
pression. As irisin is able to activate
Pgc1a gene expression in adipocytes
(Wrann et al., 2013), it would be inter-
esting to investigate whether the circu-
lating EF, a different FNDC5 cleavage
product, stimulates hippocampal Pgc1a
gene expression, which in turn induces
Erra gene expression and then Fndc5
gene expression in the same neurons614 Cell Metabolism 18, November 5, 2013 ª(Figure 1). In this way, the action of the
circulating EF in hippocampus would be
amplified. Neuronal activity may not be
critically involved in exercise-induced
Bdnf gene expression in the hippo-
campus, because exercise induces ex-
pression of several activity-dependent
genes, such as Arc, cFos, and Zif268, in
many brain regions, but Bdnf only in the
hippocampus (Wrann et al., 2013). Other
transcription factors such as CREB and
NF-kB have also been proposed to
mediate exercise-induced hippocampal
Bdnf gene expression (Mattson, 2012).
Since the Bdnf gene is transcribed from
multiple distinct promoters (Pruunsild
et al., 2007), it remains to be determined
if EF, CREB, and NF-kB act in the same
signaling cascade or on the same pro-
moter to increase hippocampal BDNF
levels.
As human life expectancy increases,
age-related cognitive decline and Alz-
heimer’s disease have become leading
health issues. The study by Wrann et al.
(2013) reveals a critical role for FNDC5 in
mediating beneficial effects of exercise
on brain health, which moves a step
closer to identifying the EF, and will
certainly have important implications for
age-related health issues. Identification2013 Elsevier Inc.of the EF may allow aged people to reap
the benefit of exercise for their brains
without going through the challenge of
endurance exercise.REFERENCES
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Atherosclerosis is driven by the release of cytokines from macrophages, and the b isoform of interleukin-1
(IL-1b) is aprime suspect indiseaseprogression. Freiganget al. (2013) nowsuggest that IL-1a, a close relative,
is selectively induced by fatty acids independent of the inflammasome to promote vascular inflammation.Cytokines evolved as part of the immune
response to protect mammals from an
environment filled with threats, but those
threats now include an overeating-induced excess of lipids that prompts
cytokine responses more appropriate for
pathogens. That cytokines mediate dis-
ease is now well established in metabolicand vascular medicine, but the precise
cytokines involved in atherosclerosis
and their relative importance are still
under debate. A large body of evidence
Figure 1. Inflammatory Cytokines Promote Atherosclerosis
Macrophages secrete IL-1b (bottom), which is thought to be important in this process, but recent evidence
implicates IL-1a (top) through a mechanism involving fatty acid-induced respiratory uncoupling and
alterations of calcium flux.
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Previewssuggests that interleukin-1 (IL-1) signaling
is proatherogenic. Two prominent mem-
bers of the IL-1 family are the isoforms
IL-1a and IL-1b, which use a shared re-
ceptor, the interleukin-1 receptor type I
(IL-1R1), to promote downstream
signaling pathways. Of the two isoforms,
IL-1b is by far the more extensively stud-
ied. In fact, the ongoing Canakinumab
Anti-inflammatory Thrombosis Outcomes
Study (CANTOS) is evaluating the efficacy
of IL-1b inhibition in reducing cardiovas-
cular events in one of the first true tests
of the inflammation hypothesis of athero-
sclerosis in humans (Ridker et al., 2011).
However, the biology of IL-1 signaling is
complex, and the role played by IL-1b
may be less than explicit. Although mice
deficient in IL-1b (Kirii et al., 2003) or in-
jected with anti-iL-1b neutralizing anti-
body (Bhaskar et al., 2011) have reduced
plaque formation, deficiency of IL-1a has
been reported to afford more protection
from atherosclerosis (Kamari et al.,
2007). Mice deficient in IL-1R1 have a
complex phenotype that includes fea-
tures suggestive of plaque instability
(Alexander et al., 2012). Both IL-1a and
IL-1b lack a signal sequence required for
conventional secretory pathways, and
they appear to utilize different mecha-
nisms for secretion. The NLR family, pyrin
domain-containing 3 (NLRP3) inflamma-some is essential for IL-1b secretion,
whereas IL-1a secretion can be induced
by inflammasome-independent mecha-
nisms that involve calcium flux (Gross
et al., 2012).
A recent study (Freigang et al., 2013)
sheds light on the roles of macrophage
IL-1a and IL-1b in the context of athero-
sclerosis. Freigang et al. (2013) trans-
planted bone marrow from mice lacking
either IL-1a or IL-1b into animals that are
prone to develop diet-induced athero-
sclerosis, low-density lipoprotein (LDL)
receptor-deficient mice. This manipula-
tion resulted in atherosclerosis-suscepti-
ble mice with a deficiency in IL-1a
or IL-1b limited to the hematopoietic
compartment. After 4 months of an
atherogenic diet containing 0.5% choles-
terol, mice lacking bone marrow-derived
IL-1a had fewer atherosclerotic lesions
than controls, and the effect was more
pronounced than that in mice lacking
bone marrow-derived IL-1b, confirming
previous results (Kamari et al., 2007). In
a different atherosclerosis-prone mouse
model with normal expression of IL-1 iso-
forms (the apoE-deficient mouse), lipid
mass spectrometry analysis of lesions
after 3 months of atherogenic feeding
showed a predominance of the saturated
fatty acids palmitate (16:0) and stearate
(18:0). Then, 3 months later, afterCell Metabolism 18,6 months of atherogenic feeding, oleic
acid (18:1) was most abundant and there
were increases in other unsaturated fatty
acids, such as linoleate (18:2).
When wild-type macrophages were
first activated by lipopolysaccharide,
treatment with oleic acid induced IL-1a,
but not IL-1b, secretion. Some other un-
saturated fatty acids had the same effect.
Saturated fatty acids did not stimulate the
release of either isoform. Oleic acid-
induced IL-1a secretion was inflamma-
some independent. Mice fed an oleic
acid-enriched diet for 12 weeks had
more atherosclerosis than mice fed a
chow diet. Additional data in cultured
bone marrow-derived macrophages
suggested that the promotion of IL-1a
secretion to the exclusion of IL-1b secre-
tion was mediated by oleic acid-induced
mitochondrial respiratory uncoupling,
leading to increased calcium flux.
Vascular respiratory uncoupling is known
to increase atherosclerosis (Bernal-Mizra-
chi et al., 2005).
Although oleic acid induces IL-1a
secretion in primed macrophages, it is
not clear that this process is entirely inde-
pendent of IL-1b. Freigang et al. (2013)
also injected oleic acid to induce perito-
nitis. Neutrophil migration was blunted
in mice transplanted with bone marrow
deficient in either IL-1a or IL-1b. However,
antibodies to IL-1a, but not to IL-1b,
protected against oleic acid-induced
neutrophil migration, suggesting an
intracellular requirement of IL-1b for
IL-1a secretion. Since neutrophils are
not a major contributor to diet-induced
atherosclerosis, it would be of interest
to know if mice deficient in IL-1a or IL-1b
are protected from oleic acid-induced
atherosclerosis.
The discovery of selective induction of
secretion of macrophage IL-1a by oleic
acid and other unsaturated fatty acids is
intriguing (Figure 1), but a looming issue
is the overall significance of this pathway
to atherogenesis. It is curious that lipid
analysis of lesions closest to the time
of a demonstrated protective effect of
IL-1a deficiency showed a predominance
of saturated fatty acids, which are appar-
ently incapable of stimulating IL-1a
secretion. Lipid analysis at 6 months
showed enrichment with oleic acid, re-
flecting a phenomenon first described in
de novo lipogenesis studies more than
40 years ago: as cholesterol-inducedNovember 5, 2013 ª2013 Elsevier Inc. 615
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Previewsatherosclerotic lesions progress, oleic
acid becomes more abundant in lesions,
as it is preferentially used to form choles-
teryl esters (St Clair et al., 1968). The
authors studied responses of cells to
free (unesterified) fatty acids, but fatty
acids in cells are rapidly modified and
incorporated into cholesteryl esters
(comprising more than 80% of the lipid
mass of fatty streaks), phospholipids, tri-
glycerides, and other forms. It is unclear
how free oleate would be trafficked from
one of these sites to the mitochondrial
membrane to induce respiratory uncou-
pling. It is also difficult to reconcile this
mouse work with a large body of human
data indicating that oleic acid-enriched
diets decrease clinical atherosclerosis.
In one striking example, a randomized
trial recently showed that humans
assigned to a Mediterranean diet sup-
plemented with extra virgin olive oil
(consisting mostly of oleic acid with
some of the other unsaturated fatty acids
shown to increase IL-1a secretion in the
Freigang study) had fewer major cardio-
vascular events (Estruch et al., 2013).
Freigang et al. (2013) present important
findings that expand our understanding616 Cell Metabolism 18, November 5, 2013 ªof macrophage biology. Their work dem-
onstrates that IL-1a can be selectively
induced without increasing IL-1b secre-
tion and implicates unsaturated fatty
acids in this effect. The idea that IL-1b is
the dominant family member promoting
vascular wall inflammatory dysfunction
may be naive. The poet and satirist
Alexander Pope is credited with the
observation that a family is but too often
a commonwealth of malignants. In
atherosclerosis, the interleukin family is
dysfunctional, but additional studies will
be required to clarify which member,
IL-1a or IL-1b, is most malignant in medi-
ating progression of vascular disease in
a world intent on promoting inflammation
by eating too much.ACKNOWLEDGMENTS
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